Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Zhilong Yang · TEXAS A&M AGRILIFE RESEARCH · 2023 · $183,220 — Poxviruses are a large family of viruses including species that are highly pathogenic for humans and animals, including smallpox and monkeypox viruses. Some poxviruses are developed as vaccine vectors and oncolytic virotherapies to fight other infectious diseases and cancers. Vaccinia virus, the pro…
David Gaddes · CFD RESEARCH CORPORATION · 2023 · $343,491 — Project Summary/Abstract: Computational techniques for gene engineering, such as codon optimization, use synonymous codon changes to increase protein production. Applications for these computational gene optimizations include recombinant protein drugs, nucleic acid therapies, and mRNA vaccines. Alth…
Bing Chen · BOSTON CHILDREN'S HOSPITAL · 2023 · $841,863 — Summary Structural insights from our recent work provide a strong scientific premise for exploring the membrane-related components of HIV-1 envelope glycoprotein (Env), including the membrane proximal external region (MPER), the transmembrane domain (TMD) and the cytoplasmic tail (CT), for vaccine d…
Brian Geiss · COLORADO STATE UNIVERSITY · 2022 · $374,993 — Approximately 2/3rd of the world population is at risk of infection by at least one of the 35 insect-borne flaviviruses known to cause disease in humans. There are currently few vaccines and no therapeutics available to treat patients infected by flaviviruses such as Dengue, Zika, and West Nile viru…
JOHN H. SAMPSON · DUKE UNIVERSITY · 2022 · $400,950 — ABSTRACT We have previously reported in Nature that patients with newly-diagnosed glioblastoma (GBM) randomized to receiving vaccines against Cytomegalovirus (CMV) using a potent vaccine site preconditioning regimen had a statistically significant increase in progression-free survival (PFS) and over…
Beth Ann Tamburini · UNIVERSITY OF COLORADO DENVER · 2022 · $188,825 — Project Summary Live attenuated vaccinations generate both humoral and cellular immune memory, accounting for much of the increased duration of protective immune memory. As increased protective immune memory to live attenuated vaccines is of critical importance, understanding the mechanisms of this …
Afamefuna Okoye · OREGON HEALTH & SCIENCE UNIVERSITY · 2022 · $823,817 — PROJECT SUMMARY Although the advent of combination antiretroviral therapy (cART) has dramatically improved the prognosis of people living with human immunodeficiency virus (HIV), cART alone cannot eradicate the infection and, therefore, daily treatment must be maintained for life to prevent relapse …
Norbert Pardi · UNIVERSITY OF PENNSYLVANIA · 2022 · $613,686 — ABSTRACT Influenza virus is one of the most important human infectious diseases. The influenza mortality is estimated to be approximately 650,000 per year worldwide, in addition, occasional global pandemics can infect up to 20- 40% of the world's population. Licensed influenza virus vaccines require…
Zhilong Yang · TEXAS A&M AGRILIFE RESEARCH · 2022 · $378,750 — Project Summary Although smallpox had been eradicated, the chance the virus could arise from unknown stocks or de novo synthesis remains a credible biothreat. Moreover, other poxviruses cause significant morbidity and mortality in humans and economically important animals; and poxviruses are widely …
Adolfo Garcia-Sastre · JACKSON LABORATORY · 2022 · $1,622,607 — PROJECT SUMMARY The WHO estimates that annual epidemics of influenza result in 3-5 million cases of severe illness and 300,000- 500,000 deaths. 90% of influenza-related deaths occur in older adults despite widespread vaccination programs with vaccines tailored for this high-risk group. The estimated…
Rhiju Das · STANFORD UNIVERSITY · 2022 · $684,690 — PROJECT SUMMARY The continuing discoveries of RNAs and their critical roles in cellular and viral machinery are inspiring novel antibacterial, antitumor, antiviral, and genome-editing therapies based on disabling, manipulating, and repurposing the RNAs involved. Unfortunately, our poor biophysical u…
Sean PJ Whelan · WASHINGTON UNIVERSITY · 2022 · $561,330 — This application is to extend a MERIT award to study RNA synthesis in minus-strand RNA viruses. Nonsegmented negative-sense (NNS) RNA viruses include some of the most significant human pathogens that are an ongoing threat to US public health. For measles, mumps and rabies there are licensed vaccines…
Beth Ann Tamburini · UNIVERSITY OF COLORADO DENVER · 2022 · $459,647 — Project summary: We and others have demonstrated that antigens derived from infectious viral infections persist in the host for extended periods of time, well beyond the time in which the infection is cleared from the host. Our lab has specifically identified that antigens derived from both vaccinat…
Yogesh K Gupta · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · 2022 · $626,308 — ABSTRACT The massive global pandemic with high morbidity and mortality makes Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) one of the deadliest viruses in recent history. It is especially noteworthy for hijacking the normal operations of human cells. To develop effective therapies, we…
Norbert Pardi · UNIVERSITY OF PENNSYLVANIA · 2022 · $626,397 — ABSTRACT Vaccines prevent hundreds of millions of illnesses and save millions of lives every year. Various types of licensed vaccines (live attenuated and inactivated pathogens, adjuvanted protein subunits) provide some level of protection against a variety of dangerous illnesses. However, there are…
Gabriel D Victora · ROCKEFELLER UNIVERSITY · 2022 · $454,516 — PROJECT SUMMARY/ABSTRACT Germinal centers (GCs) are site of antibody somatic hypermutation (SHM) and affinity maturation, and are therefore essential for effective humoral immune responses to pathogens. Efficient affinity maturation in GCs requires that B cells cycle between two different cell state…
PAUL L FOX · CLEVELAND CLINIC LERNER COM-CWRU · 2022 · $402,500 — Project Summary/Abstract Obesity is an epidemic-scale problem in the U.S. affecting about 35% of the adult population, and is a major risk factor for the ongoing pandemic, COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the RNA betacoronavirus that is the causative agent of…
Craig A Elmets · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2022 · $222,750 — ABSTRACT Sunlight is the major environmental agent to which humans are exposed. Although it has beneficial effects (e.g. metabolism of vitamin D, energy necessary for life), chronic overexposure to the ultraviolet portion causes DNA damage, premature aging of the skin, immunosuppression and non-mela…
Connor R. Gorman · SYNSHARK LLC · 2022 · $257,003 — Project Summary/Abstract In this grant application, SynShark (SBA Certified Small Business), in collaboration with North Carolina State University, will demonstrate a new plant source for pharmaceutical grade squalene as a natural adjuvant. The team will utilize novel plant-engineering routes to st…
Dipak Kumar Raj · UNIVERSITY OF SOUTH FLORIDA · 2022 · $368,800 — Project Summary The overall aim of this application is to advance PfCDPK5 and PfGARP as vaccine candidates for falciparum malaria. P.falciparum malaria affects almost one-half of the world's population and causes more than 500,000 deaths annually. Young children in malaria endemic areas of Africa h…